Tumor Cells Transfected with a Bacterial Heat-Shock Gene Lose Tumorigenicity and Induce Protection against Tumors
By Katalin V. Lukacs, Douglas B. Lowde, Richard W. Stokes, and M. Joseph Colston

From the National Institute for Medical Research, London NW7 1AA, United Kingdom

Summary
The gene encoding a highly immunogenic mycobacterial heat-shock protein (hsp65) was transfected into the murine macrophage tumor cell line J774. The resulting hsp65-expressing cells (J774-hsp65) were no longer able to produce tumors in syngeneic mice. This loss of tumorigenicity was not mediated through T cells since the transfected cells did not produce tumors in athymic mice. If mice are first immunized with the J774-hsp65 cells and then challenged with the parent J774 cells, the mice do not develop tumors, indicating that the presence of the mycobacterial hsp65 protein greatly enhances immunological recognition of unique structures expressed by the parent tumor cells. This is further confirmed by the demonstration in vitro of T cells derived from J774-hsp65-immunized mice that are cytotoxic for the parent J774 cells. The results provide the basis for a novel strategy for enhancing the immunological recognition and decreasing the tumorigenicity of transformed cells.

Heat-shock proteins (hsp's) are molecular chaperones, mediating the assembly and folding of other proteins (1-5). They have been reported to be expressed at abnormal levels in tumor cells (6-9), and in a murine sarcoma model, the tumor-specific antigen has been shown to be a hsp (10). They are among the most immunogenic molecules known (11-14). The cause of this immunodominance is thought to reside in their universal distribution and high degree of sequence conservation, resulting in continuous priming of the immune system. Mycobacterial hsp's have been used as carrier molecules for circumventing the need for adjuvants to greatly enhance immune responses to unrelated antigens (15, 16).

Although spontaneously arising tumors are usually very weakly antigenic, their recognition by cytotoxic T cells and elimination in vivo can be greatly enhanced if they are engineered to express cytokine genes such as IL-2 (17) or IL-4 (18). Thus, such cells must express unique structures that can be targets for immunological recognition. In an alternative approach to enhance specific immunity to tumor cells, we have transfected a highly malignant macrophage tumor cell line with the mycobacterial 65-kD hsp-encoding gene (hsp65). We find that not only do hsp65-expressing tumor cells lose their tumorigenicity in mice, but immunization of mice with the transfected cells induces strong T cell-mediated cytotoxic responses against the parent untransfected cells, and such mice are protected against challenge with the parent cells. The transfer of cytokine genes for cancer therapy has been widely reported, and in some cases has reached the stage of clinical trials (19, 20); transfer of the mycobacterial 65-kD hsp gene to tumor cells represents a novel strategy for an immunotherapeutic or immunoprophylactic approach to cancer.

Materials and Methods

Cells and Cell Culture. Psi-CRE, J774G8 (J774; reference 21) cells and its transfected derivate (J774-vector and J774-hsp65) were maintained in DME with 10% newborn calf serum. WEHI 164 and Pu518 cells were maintained in RPMI 1640 with 12% FCS. All media contained 100 μg/ml streptomycin, 100 μg/ml penicillin, 1 mM l-glutamine, and 10 mM Hepes.

Transfection of J774 cells with the Mycobacterium leprae hsp65 Gene. The transfection was carried out as described previously (22, 23). Briefly, the M. leprae 65-kD hsp gene was cloned into the retroviral shuttle vector pZIPNeoSV(x). This was transfected by calcium phosphate precipitation into the virus-packaging cell line psi-CRE. The helper-free, replication-defective, ecotropic retroviruses obtained were used to infect J774 tumor cells. Infected J774-hsp65 cells were selected by cultivating in 0.8 mg/ml neomycin (G418; Sigma Chemical Co., St. Louis, MO). Expression of the 65-kD hsp gene was assessed by Northern and Western blotting and by FACS analysis (Becton Dickinson & Co., Mountain View, CA) of cells after indirect labeling using mAb CIII8, which recognizes the M. leprae 65-kD protein, and FITC-labeled sheep anti-mouse F(ab')2 antibody (Boehringer, Mannheim, Germany). J774 cells transfected with vector alone (J774-vector) were prepared in parallel.

mAbs and Immunofluorescence. mAbs against H-2K, Fcy2 receptor, LFA-1, and Pgp-1 (CD44) were obtained from PharMingen.
Inoculation and Immunization of Mice. Six to 12-wk-old female BALB/c, BALB/c athymic, or CBA mice were obtained from breeding colonies at the National Institute for Medical Research. For the production of tumors mice were inoculated intraperitoneally with the stated number of tumor cells taken from subconfluent cell cultures. Mice were immunized with J774 hsp65 cells by four intraperitoneal injections of 10^6 cells given at weekly intervals.

Assessment of Tumor Size. Since tumors grew in most abdominal organs, resulting in an unseparable aggregation of primary tumor and abdominal organs, tumor size was calculated by weighing the primary tumor and abdominal organs of the test mice, and subtracting the weight of abdominal organs for five age-matched normal controls.

Cytotoxicity Assays. Mice were immunized with four intraperitoneal injections of 10^6 cells at weekly intervals. On day 28, spleens were removed and single-cell suspensions prepared in RPMI 1640 plus 10% FCS. The cells were incubated with 6 d with J774-hsp65 cells γ irradiated by 30 Gy. B cells were removed by panning on rabbit anti-mouse IgG-coated plates. CD4 and CD8 T cell subsets were purified as described previously (24). Briefly, NK, CD4, and/or CD8 cells were removed by treatment of cells (10^7/mI) with 10 μg/ml PK136 (anti-NK1.1; PharMingen) and anti-L3T4 and/or anti-Lyt-2 (Becton Dickinson & Co.) mAbs at 4°C for 30 min, followed by incubation with a 1:10 dilution of rabbit complement at 37°C for 60 min, resulting in CD4 and CD8 populations that were >90% pure as judged by FACScan® analysis. To measure cytotoxic activity, varying numbers of CD4 or CD8 effector cells were incubated with 2,000 target cells per well labeled with ^51Cr in triplicate wells for 6 h at 37°C in a V-bottomed 96-well microtiter plate. ^51Cr release was measured in wells containing effector T cells and target cells (cpmExperimental), wells containing target cells incubated in medium alone (cpmExperimental), and in wells containing target cells plus 0.1% Triton X-100 (cpmExperimental). Percent cytotoxicity was calculated using the formula: 100 × (cpmExperimental - cpmControl) / cpmControl. Target cells (J774, hsp65, J774, Ps518, or Wehi 164) were labeled with ^51Cr by incubating 10^6 cells with 3.7 MBq of ^51Cr in 0.5 ml RPMI containing 20% FCS for 2 h, then washing three times.

Results and Discussion

The murine macrophage tumor cell line J774 was transfected with the M. leprae hsp65-encoding gene as previously described (22, 23). Expression of the bacterial hsp was confirmed using mAbs directed to the bacterial hsp (not shown). J774 is a BALB/c-derived cell line; the tumorigenicity of the parent (J774) cell line and the hsp-transfected (J774-hsp65) cells was tested in euthymic and athymic BALB/c and in CBA mice. Euthymic BALB/c mice that received either the J774 cell line or the J774 cell line transfected with the vector alone (J774-vector) developed tumors within 3 wk when given 10^6 cells (Table 1 and Fig. 1). These were large, highly malignant lymphoreticular neoplasms composed of histiocytic cells with many mitoses and cellular pleomorphisms with metastases in the spleen, liver, kidney, mesentry, and lung.

| Injected tumor cells | Dose | BALB/c | Athymic | CBA |
|----------------------|------|--------|---------|-----|
| J774                 | 10^6 | 4/5    | -/10    | -/10|
| J774-hsp65           | 10^6 | 0/10   | 0/10    | 0/10|
| J774-hsp65           | 10^7 | 1/10   | 2/10    | -/10|
| J774                 | 10^7 | 0/5    | -/10    | -/10|

Mice were inoculated intraperitoneally with the indicated number of tumor cells resuspended in 0.5 ml endotoxin-free PBS. Tumor cells were either the parent cell line (J774), the parent cell line transfected with the mycobacterial hsp65 gene (J774-hsp65), or the parent cell line transfected with the vector alone (J774-vector). Tumor incidence was determined by autopsy and histological examination 21 d after injection of cells.

In an attempt to identify the underlying mechanism for their loss of tumorigenicity, J774-hsp65 cells did not develop tumors. This loss of tumorigenicity of J774-hsp65 cells did not appear to be due to rejection by T cells, as a similar loss of tumorigenicity was seen in athymic mice, but could involve NK cell or antibody-mediated killing. It is unlikely to be due to a chance insertion of the foreign gene into a gene involved in tumorigenicity since we obtained exactly the same results with two independently derived hsp65-transfected J774 cell lines. Neither the parent cell line nor the transfected tumor cells produced tumors in CBA mice, confirming their inability to grow across an MHC barrier.

In an attempt to identify the underlying mechanism for their loss of tumorigenicity, J774-hsp65 cells were compared with the parent cell line for differences in in vitro growth rate, expression of MHC class I and II molecules, and a variety of cell markers (including Fc and C3b receptor, LFA-1, CD44, and p53) thought to play a role in cellular interactions, tumorigenicity, or metastatic potential, and for expression of cytokine genes. There was elevated intracellular expression of p53 in the hsp-transfected cells (data not shown). Lost tumorigenicity of the transfected cells could result from the interaction of the hsp with p53, the protein encoded by the p53 tumor suppressor gene. Mutations in the p53 gene resulting in dysfunctional p53 protein are the most frequently observed genetic lesions in tumors (25). P53 is a DNA-binding protein essential for normal cell cycle control, and hsp chaperones play a crucial role in its conformation and function (26, 27). Thus, the increased efficiency of chaperone activity in the hsp-65-transfected cells could result in the proper folding and conformation of ineffective p53 protein, thereby correcting its loss of tumor suppressor function. The association be-
Figure 1. Growth of transfected tumor cells in normal (A) and athymic (B) BALB/c mice. Tumor cells were either the parent J774 cells (●), the parent cell line transfected with vector alone (J774-vector) (▲), or the parent cell line transfected with the mycobacterial hsp65 gene (J774-hsp65) (■). Mice were injected intraperitoneally with 10^6 cells, and tumor size was calculated by weighing the primary tumor and abdominal organs of the test mice and subtracting the weight of abdominal organs of five age-matched normal controls. For each cell type, 20 mice were inoculated. Five mice were killed on days 7 and 14, and 10 on day 21.

Figure 2. Growth of tumor cells in normal (A) and athymic (B) BALB/c mice that had been immunized with J774-hsp65 cells. Mice were immunized with four intraperitoneal injections of 10^6 J774-hsp65 cells at weekly intervals, and then challenged on day 28 with tumor cells of differing origin. The results show tumor size 21 d after challenge in immunized (■) and nonimmunized control (▲) mice. Tumor size was calculated by weighing the primary tumor and abdominal organs of the challenged mice, and subtracting the weight of abdominal organs of age-matched normal controls. The dotted line represents the mean + 2 SD for the weight of internal organs of the control mice. *A positive size is recorded, as the weight of internal organs of these mice exceeded those of control mice; however, no tumors could be detected in these mice, either macroscopically or histopathologically.

tween loss of tumorigenicity and elevated p53 expression is currently being investigated.

We next investigated whether mice that had received the transfected J774 cells showed any level of protection against developing tumors when challenged with the parent cell line. The results (Table 2 and Fig. 2) demonstrate a highly significant level of protection; J774 produced tumors in naive mice, but not in mice that had previously been immunized with J774-hsp65 cells. This was confirmed by autopsy and histological examination in which no evidence of tumor cells or autoimmune inflammation could be found. A second group of challenged mice were completely healthy 6 mo after challenge, and 80% have survived for >12 mo. The protection generated by J774-hsp65 cells appeared to be mediated by T cells, since immunized athymic mice all developed tumors after subsequent challenge.

To investigate the specificity of the protective effect, immunized mice were challenged with two other cell lines: Pu518, which is an unrelated, spontaneous reticulum sarcoma of BALB/c origin, and Wehi 164 cells, derived from a methylcholanthrene-induced BALB/c sarcoma. The results (Table 2 and Fig. 2) show significant protection against challenge with Pu518, but not with Wehi 164 cells. When mice were immunized with irradiated J774 cells they were partially protected against subsequent challenge (Table 2). This indicates that J774 cells do have tumor-associated antigens that normally do not induce an effective immune response; the presence of the 65-kD hsp in transfected cells presumably enhances this response.

Since protection appeared to be T cell mediated, we investigated the relationship between protection in vivo and T cell-mediated cytotoxicity in vitro. Nonadherent spleen cells from mice immunized with J774-hsp65 cells were cultured in vitro with irradiated J774-hsp65 cells for 6 d. Purified populations of CD4 or CD8 T cells were tested for cytotoxicity using J774, J774-hsp65, Pu518, and Wehi 164 cells as targets (Figs. 3 and 4). Both CD4 and CD8 populations were highly cytotoxic for J774-hsp65 and for the parent J774 cells; depl-
Mice, either normal or athymic BALB/c, were immunized with four intraperitoneal injections of $10^6$ J774-hsp65 cells or γ irradiated (30 Gy) J774-vector cells, given at weekly intervals. On day 28 the mice were challenged intraperitoneally with $10^6$ reticulum sarcoma cells of differing origins. Tumor incidence was determined by autopsy and histological examination 21 d after challenge.

Table 2. The Effect of Immunization with Transfected Tumor Cells (J774-hsp65) on Subsequent Challenge with Reticulum Sarcoma Cells

| Immunization     | Challenge    | BALB/c BALB/c |       |       |
|------------------|--------------|---------------|-------|-------|
|                  |              | normal        | athymic |
| J774-hsp65       | J774         | 0/10          | 5/5   |
| None             | J774         | 9/10          | 5/5   |
| J774-hsp65       | J774-vector  | 0/15          | 5/5   |
| None             | J774-vector  | 10/10         | 5/5   |
| J774-hsp65       | Pu518        | 2/10          | 5/5   |
| None             | Pu518        | 5/5           | 4/4   |
| J774-hsp65       | Wehi 164     | 7/9           | 5/5   |
| None             | Wehi 164     | 5/5           | 4/4   |
| Irradiated J774-vector | J774     | 4/9           | 5/5   |
| None             | J774         | 8/10          | 5/5   |

Figure 4. In vitro cytotoxic activity of splenocytes from mice immunized with J774-hsp65 cells. Mice were immunized with four intraperitoneal injections of $10^6$ J774-hsp65 cells at weekly intervals. Spleen cells were cultured for 6 d with irradiated J774-hsp65 cells, and purified populations of CD4 or CD8 cells were tested for cytotoxicity against J774-hsp65 (□), J774 (△), Pu518 (◇), and Wehi 164 (○) cells. The results are shown as the mean ± SD.

Figure 3. In vitro cytotoxic activity of splenocytes from mice immunized with J774-hsp65 cells. Mice were immunized with four intraperitoneal injections of $10^6$ J774-hsp65 cells at weekly intervals. Spleen cells were cultured for 6 d with irradiated J774-hsp65 cells, and purified populations of CD4 or CD8 cells were tested for cytotoxicity against J774-hsp65 (□), J774 (△), Pu518 (◇), and Wehi 164 (○) cells. Cells depleted of both CD4 and CD8 cells were also included (■). The results are shown as the mean ± SD.

We assume that the highly immunogenic nature of the
References

1. Langer, T., C. Lu, H. Echols, J. Flanagan, M.K. Hayer, and F.U. Hartl. 1992. Successive action of DnaK, DnaJ and GroEL along the pathway of chaperone-mediated protein folding. Nature (Lond.). 356:682.

2. Sherman, M.Y., and A.L. Goldberg. 1992. Heat shock in Escherichia coli alters the protein-binding properties of the chaperonin groEL by inducing its phosphorylation. Nature (Lond.). 357:167.

3. Craig, E.A. 1985. The heat shock response. CRC Crit. Rev. Biochem. 20:239.

4. Lindquist, S. 1986. The heat shock response. Annu. Rev. Biochem. 55:1151.

5. Goloubinoff, P., A.A. Gatenby, and G.H. Lorimer. 1989. GroE heat-shock proteins promote assembly of foreign prokaryotic ribulose bisphosphate carboxylase oxygenases in Escherichia coli. Nature (Lond.). 337:44.

6. Bensaude, O., and M. Morange. 1983. Spontaneous high expression of heat-shock proteins in mouse embryonal carcinoma cells and ectoderm from day 8 mouse embryo. EMBO (Eur. Mol. Biol. Organ.) J. 2:173.

7. Finlay, C.A., P.W. Hinds, T.H. Tan, D. Eliyahu, M. Oren, and A.J. Levine. 1988. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mole. Cell. Biol. 8:531.

8. Fugua, S.A.W., M. Blum-Salingaros, and W.L. McGuire. 1989. Induction of the estrogen-regulated "24K" protein by heat shock. Cancer Res. 49:4126.

9. Adams, D.J., H. Haji, D.P. Edwards, R.J. Bjercke, and W.L. McGuire. 1983. Detection of a Mr 24,000 estrogen-regulated protein in human breast cancer by monoclonal antibodies. Cancer Res. 43:4297.

10. Ullrich, S.J., E.A. Robinson, L.W. Law, M. Millingham, and E. Appella. 1986. A mouse tumor-specific transplantation antigen is a heat shock-related protein. Proc. Natl. Acad. Sci. USA. 83:3121.

11. S.H.E. Kaufmann. 1990. Heat shock proteins and the immune response. Immunol. Today. 11:29.

12. Cohen, I.R., and D.B. Young. 1991. Autoimmunity, microbial immunity and the immunological homunculus. Immunol. Today. 12:105.

13. Young, D.R., R. Lathigra, R. Hendrix, D. Sweetser, and R.A. Young. 1988. Stress proteins are immune targets in leprosy and tuberculosis. Proc. Natl. Acad. Sci. USA. 85:4267.

14. Young, R.A., and T.J. Elliot. 1989. Stress proteins, infection and immune surveillance. Cell. 59:5.

15. Lussow, A.R., C. Barrios, J. van Embden, R. van der Zee, A.S. Verdini, A. Pessi, J.A. Louis, P.H. Lambert, and G. Del Giudice. 1991. Mycobacterial heat-shock proteins as carrier mol-

We thank Professor P. L. Lantos for carrying out the histological examination of the tumors and tissues.

Address correspondence to M. Joseph Colston, Laboratory for Leprosy and Mycobacterial Research, National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom. Richard Stokes' present address is the Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC V52 4H4, Canada.

Received for publication 26 October 1992 and in revised form 10 March 1993.
ecules. *Eur. J. Immunol.* 21:2297.

16. Barrios, C., A.R. Lussow, J. Van Embden, R. Van der Zee, R. Rappuoli, P. Constantino, J.A. Louis, P.H. Lambert, and G. Del Giudice. 1992. Mycobacterial heat-shock proteins as carrier molecules. II. The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming. *Eur. J. Immunol.* 22:1365.

17. Fearon, E.R., D.M. Pardoll, T. Itaya, P. Golubek, H.I. Levitsky, J.W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. *Cell.* 60:397.

18. Golubek, P.T., A.J. Lazenby, H.I. Levitsky, L.M. Jaffee, H. Karasuyama, M. Baker, and D.M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. *Science (Wash. DC).* 254:713.

19. Gutierrez, A.A., N.R. Lemoine, and K. Sikora. 1992. Gene therapy for cancer. *Lancet.* 339:715.

20. Miller, A.D. 1992. Human gene therapy comes of age. *Nature (Lond.)* 357:455.

21. Ralph, P., J. Prichard, and M. Cohn. 1975. Reticulum cell sarcoma: an effector cell in antibody-dependent cell-mediated immunity. *J. Immunol.* 114:898.

22. Silva, C.L., A. Palacios, M.J. Colston, and D.B. Lowrie. 1992. *Mycobacterium leprae* 65-kDa antigen expressed from a retroviral vector in a macrophage cell line is presented to T cells in association with MHC class II in addition to MHC class I. *Mycobacterial Pathog.* 12:27.

23. Silva, C.L., K. Lukacs, and D.B. Lowrie. 1993. Major histocompatibility complex non-restricted presentation to CD4+ T lymphocytes of *Mycobacterium leprae* heat shock protein 65 antigen by macrophages transfected with the mycobacterial gene. *Immunology.* 78:35.

24. Lukacs, K., and R.J. Kurlander. 1989. MHC-unrestricted transfer of antilisterial immunity by freshly isolated immune CD8 spleen cells. *J. Immunol.* 143:3731.

25. Hollstein, M., D. Sidransky, B. Vogelstein, and C.C. Harris. 1991. p53 mutations in human cancer. *Science (Wash. DC).* 253:49.

26. Gannon, J.V., and D.P. Lane. 1991. Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. *Nature (Lond.)* 349:802.

27. Hainaut, P., and J. Milner. 1992. Interaction of heat-shock protein 70 with p53 translated in vitro: evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation. *EMBO (Eur. Mol. Biol. Organ.) J.* 11:3513.

28. Vyakarnam, A., P.J. Lachmann, and D.Y. Sia. 1988. The killing of tumor cell targets coupled to tuberculin (PPD) by human and murine PPD-reactive T helper clones. I. PPD specificity of killing. *Scand. J. Immunol.* 27:337.

29. Vyakarnman, A., and P.J. Lachmann. 1988. The killing of tumor cell targets coupled to tuberculin (PPD) by human and murine PPD-reactive T helper clones. II. Major histocompatibility complex restriction of killing. *Scand. J. Immunol.* 27:347.

30. Munk, M.E., B. Schoel, and S.H.E. Kaufmann. 1988. T cell responses of normal individuals towards recombinant protein antigens of *Mycobacterium tuberculosis*. *Eur. J. Immunol.* 18:1835.

31. Fischer, H.P., C.E.M. Sharrock, and G.S. Panayi. 1992. High frequency of cord blood lymphocytes against mycobacterial 65-kDa heat shock protein. *Eur. J. Immunol.* 22:1667.

32. Kawakami, Y., R. Zakut, S.L. Topalian, H. Stotter, and S.A. Rosenberg. 1992. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. *J. Immunol.* 148:638.

33. Palladino, M.A. Jr., P.K. Srivastava, H.F. Oettgen, and A.B. DeLeo. 1987. Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas. *Cancer Res.* 47:5074.

34. Culver, K.W., Z. Ram, S. Wallbridge, H. Ishii, E.H. Oldfield, and R.M. Blaese. 1992. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. *Science (Wash. DC).* 256:1550.